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Poster Session I S315served as controls. Using samples from over 20 patients in four
groups, we first conducted a discovery study to identify peptide vari-
ables that were significant across disease development (control vs.
IPS) and time (day 0 vs. day of Dx or day 14 for controls). This re-
vealed a set of 81 IPS-associated proteins that were verified by a num-
ber of methods, analyzed by ingenuity pathway analysis (IPA) and
mapped to relevant immune pathways. IPA underscored a significant
contribution of the acute phase response (TNFa / IL-6) signaling
pathway during disease progression and revealed striking similarities
between inflammation engendered during IPS in humans and mice.
In the second verification analysis, we used only samples collected on
day 0 from a larger cohort of patients to identify proteins that were
effective variables for patient stratification. Identified peptides were
subjected to predictive model building using the Ishwaran&Rao ap-
proach, which identified a set of robust plasma proteomic markers
that could 1) predict the development of IPS, and 2) identify individ-
uals who would ultimately respond to etanercept therapy. Analysis
also revealed a number of novel proteins including attractin, lumican
and LBP (the expression of which was verified by ELISA) that were
significant in the discovery analysis and classifiers for disease devel-
opment and or response to therapy. In sum, data generated in this
translational research endeavor confirm previous clinical and exper-
imental observations, provide new insights into the pathophysiology
of IPS and identify a set of robust markers predictive for disease pro-
gression and response to therapy. As anti-TNF therapies are being
developed as treatment for GVHD and other immune-mediated dis-
orders, these results uncover a set of robust markers for patient strat-
ification as a basis for individualized therapy that is ripe for further
development.296
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Background: Adenovirus infection is a serious and often fatal com-
plication in immunocompromised patients. There are currently no
FDA-approved therapies for adenovirus infection. Cidofovir has
been reported to have variable efficacy in treating Adenovirus but
is associated with significant toxicity, especially renal and possible
marrow toxicity. CMX001 is an oral Lipid -Antiviral-Conjugate
that generates high intracellular levels of the active cidofovir-diphos-
phate without evidence of cidofovir-like nephrotoxicity. CMX001 is
under investigation for the prevention of adenovirus disease.
Methods: We report on 5 patients with adenovirus disease treated
with CMX001. Data were available for . 4 weeks of treatment.
The median age was 1.9 years (Range 1.5 -11.8). The preparative
regimen for the transplant patients consisted of Alemtuzumab, Flu-
darabine and Melaphalan. The graft source was bone marrow.Table 1. Patient Characteristics
Patient Diagnosis
Days post HSCT
of ADV detection
Sites of ADV
infection
Viral Load
(copies/ml)
1 SCID N/A Blood and Stool 770 million
2 SCID due to
RAG2 mutation
-7 Blood and Stool 1.2 million
3 FHL 300 Blood, Stool and
Nasal Secretions
32,000
4 XLP/MDS 70 Blood and Stool 89,000
5 XLP 5 Blood and Stool 102,000
SCID: Severe Combined Immunodeficiency; FHL: Familial Hemophagocytic Lym
phoproliferative Disorder; BIW: twice a week; QW: weekly; TMA: ThrombotGVHD prophylaxis was cyclosporine and methylprednisolone.
Virologic response (VR) was defined as 99% drop from baseline or
undetectable adenovirus DNA by PCR in plasma. Patient character-
istics are shown in Table 1.
Results: Adenovirus disease was diagnosed at a median of 38 days
(range -7 to 300) after transplantation. All patients received intrave-
nous cidofovir for a median of 27 days (range 22-47) prior to starting
CMX001. Four of five patients (80%) had a. 1 log drop in viral load
at the end of 1 week of therapy. VRwas seen in all patients with ame-
dian time to achieve VR was 2 weeks (range 1-3). Four patients re-
ceived doses exceeding those currently being studied. No adverse
events felt to secondary to CMX001 were seen with the 4 mg/kg/
doses. Two patients developed diarrhea that was likely related to
CMX001 therapy while receiving the 2 mg/kg/dose twice weekly.
Both patients had resolution of the symptoms when CMX001 was
stopped and were able to resume therapy without recurrence of
symptoms. No other significant side effects were observed.
Discussion: Our data demonstrates that CMX001 has efficacy
against adenoviral infections with a favorable safety profile. In this
critically ill group of patients, morbidity was high which may reflect
that CMX001 is an investigational medicine and was not used as first
line therapy for adenoviral infections in our institution for these pa-
tients. Clinicians caring for immunocompromised individuals with
adenovirus infections should consider early use of CMX001 for se-
vere adenovirus infections.297
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Background: Viral infections are a major cause of morbidity and
mortality in patients receiving allogenic hematopoietic stem cell
transplantation (HSCT).With the introduction of newer condition-
ing regimens, increasing use of reduced intensity protocols and T
cell depletion, the risk of post-transplant viral infections may be in-
creasing and specific high risk groups may need to be identified as
candidates for intensive viral monitoring and pre-emptive strategies.
Here we report our experience of viral infections in children under-
going their first allogenic HSCT from January 2009-December
2010.
Methods: One hundred twenty four patients, median age 4.9 years
(range: 0.2-25.4) were identified and charts retrospectively reviewed.
Ninety-five patients underwent HSCT for non-malignant disease,
29 for malignant disease. Graft source was unrelated donor in 102
(82%) and matched related in 22 (18%). Stem cell source was bone
marrow in 94 (76%), peripheral blood stem cells in 16 (13%) and
cord blood in 14 (11%). Sixty-four patients (35 with non-malignant
disease, 29 with malignant disease) received myeloablative condi-
tioning regimens. Forty-six patients (all with non-malignant disease)Dose of CMX001
Adverse
Events
Current Status/Followup
(months)
4 mg/kg/dose BIW None Died of Disseminated
Aspergillosis infection
4 mg/kg/dose BIW None Alive and Well/ 8 months
1 dose of 4 mg/kg/dose BIW then
11 doses of 2 mg/kg/dose BIW
Diarrhea Died of Progressive
Bronchiolitis Obliterans
5 doses of 4 mg/kg/dose BIW
then 32 doses of 2 mg/kg/dose BIW
Diarrhea Alive and Well/7 months
2 mg/kg/dose BIW None Died of Pulmonary TMA
phohistiocytosis; MDS: Myelodysplastic Syndrome; XLP: X-Linked Lym-
ic Microangiopathy.
